The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice
The Flonase Allergy Relief Nasal Spray, 50 mcg per spray market achieved annual sales of approximately $384.7 million
These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions
The facility features 2,176 high-performance GPUs across the US and Europe
The initial consideration for the transaction is US$ 12 million
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The partnership will focus on advancing fault-tolerant quantum algorithms and developing clinically relevant quantum applications
Subscribe To Our Newsletter & Stay Updated
